$FEMY

Sipos Jeremy Alexander purchased $10K of FEMY

Sipos Jeremy Alexander (Chief Technology Officer) purchased 3,125 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.

Original reporting
SEC EDGAR · Sipos Jeremy Alexander
Published Aug 12, 2026, 12:44 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FEMY
Bullish
low confidence
Mentioned
$FEMY
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FEMYBullishLow
01

Why it matters

The only new information is the CTO’s $10,000 open-market purchase; it does not include guidance, contracts, litigation, or operational updates.

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no fundamental news to reprice the stock materially.

03

What to watch

The filing does not state motivations, and the absence of a 10b5-1 plan does not by itself confirm conviction or timing advantage.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-11, transaction dated 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for FEMASYS Inc.

Company-level read

Ticker impact

$FEMYBullishLow confidence
Context

FEMASYS CTO Sipos Jeremy Alexander bought 3,125 shares at $3.20 on 2026-08-07, totaling $10,000, per Form 4.

Expected impact

Limited, likely sentiment-only effect; no clear directional catalyst beyond insider signaling.

Evidence & confidence

The disclosure is a routine Form 4 insider transaction with relatively small dollar value and no accompanying company-specific operational or financial update.

Market effects

No sector-level implications disclosed; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary and may reflect diversification or compensation timing rather than a strong forward view.

Key entities

  • FEMASYS INC

    Company whose insider transaction was reported on Form 4.

  • Sipos Jeremy Alexander

    Chief Technology Officer who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$FEMYMed

FEMASYS INC (FEMY): Results of Operations and Financial Condition

FEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr

$FEMYMedAI 8/10

Femasys Stock Falls 11% Over Announcement Of $30 Mln Private Placement

Femasys Inc. (FEMY) shares fell 11.07% to $2.65 after the company announced a $30 million private placement on Nasdaq. Femasys will sell 9.37 million shares plus pre-funded warrants and warrants for 18.75 million shares, priced at $3.20. Lead investor is Nantahala Capital, with others including Rosalind Advisors. Potential extra cash proceeds up to $60 million if warrants are exercised.

$FEMYMedAI 8/10

Femasys Inc.: Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

Femasys Inc. (NASDAQ: FEMY) said it entered a $30 million private placement with accredited investors led by Nantahala Capital, with participation from other healthcare funds and management. It will sell 9,374,999 shares plus pre-funded and accompanying warrants. If all warrants are exercised, Femasys could receive up to $60 million more. Closing is expected around Aug. 10, 2026.